TISIDB

Summary
Symbol	DGKI
Name	diacylglycerol kinase, iota
Aliases	DGK-IOTA; DAG kinase iota; diglyceride kinase iota; Diacylglycerol kinase iota
Chromosomal Location	7q32.3-q33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm. Nucleus.
Domain	PF12796 Ankyrin repeats (3 copies) PF00130 Phorbol esters/diacylglycerol binding domain (C1 domain) PF00609 Diacylglycerol kinase accessory domain PF00781 Diacylglycerol kinase catalytic domain
Function	-

> Gene Ontology [ TOP ]
Biological Process	GO:0001505 regulation of neurotransmitter levels GO:0006836 neurotransmitter transport GO:0007205 protein kinase C-activating G-protein coupled receptor signaling pathway GO:0007265 Ras protein signal transduction GO:0007269 neurotransmitter secretion GO:0007270 neuron-neuron synaptic transmission GO:0007596 blood coagulation GO:0007599 hemostasis GO:0007611 learning or memory GO:0007612 learning GO:0023061 signal release GO:0030168 platelet activation GO:0030258 lipid modification GO:0034260 negative regulation of GTPase activity GO:0035249 synaptic transmission, glutamatergic GO:0042391 regulation of membrane potential GO:0044708 single-organism behavior GO:0046578 regulation of Ras protein signal transduction GO:0046579 positive regulation of Ras protein signal transduction GO:0046834 lipid phosphorylation GO:0046958 nonassociative learning GO:0046959 habituation GO:0048167 regulation of synaptic plasticity GO:0050804 modulation of synaptic transmission GO:0050805 negative regulation of synaptic transmission GO:0050817 coagulation GO:0050878 regulation of body fluid levels GO:0050890 cognition GO:0051056 regulation of small GTPase mediated signal transduction GO:0051057 positive regulation of small GTPase mediated signal transduction GO:0051346 negative regulation of hydrolase activity GO:0051966 regulation of synaptic transmission, glutamatergic GO:0060078 regulation of postsynaptic membrane potential GO:0060079 excitatory postsynaptic potential GO:0060292 long term synaptic depression GO:0099531 presynaptic process involved in chemical synaptic transmission GO:0099565 chemical synaptic transmission, postsynaptic GO:0099643 signal release from synapse GO:1900452 regulation of long term synaptic depression
Molecular Function	GO:0004143 diacylglycerol kinase activity GO:0004857 enzyme inhibitor activity GO:0005095 GTPase inhibitor activity GO:0017016 Ras GTPase binding GO:0030695 GTPase regulator activity GO:0031267 small GTPase binding GO:0051020 GTPase binding GO:0060589 nucleoside-triphosphatase regulator activity
Cellular Component	GO:0008021 synaptic vesicle GO:0030133 transport vesicle GO:0030424 axon GO:0030425 dendrite GO:0032045 guanyl-nucleotide exchange factor complex GO:0033267 axon part GO:0043025 neuronal cell body GO:0043197 dendritic spine GO:0043679 axon terminus GO:0044297 cell body GO:0044306 neuron projection terminus GO:0044309 neuron spine GO:0048786 presynaptic active zone GO:0060076 excitatory synapse GO:0070382 exocytic vesicle GO:0097060 synaptic membrane GO:0098793 presynapse GO:0098794 postsynapse GO:0099503 secretory vesicle

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04070 Phosphatidylinositol signaling system hsa00561 Glycerolipid metabolism hsa00564 Glycerophospholipid metabolism hsa01100 Metabolic pathways
Reactome	R-HSA-114508: Effects of PIP2 hydrolysis R-HSA-416476: G alpha (q) signalling events R-HSA-388396: GPCR downstream signaling R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK R-HSA-109582: Hemostasis R-HSA-76002: Platelet activation, signaling and aggregation R-HSA-162582: Signal Transduction R-HSA-372790: Signaling by GPCR

Summary
Symbol	DGKI
Name	diacylglycerol kinase, iota
Aliases	DGK-IOTA; DAG kinase iota; diglyceride kinase iota; Diacylglycerol kinase iota
Chromosomal Location	7q32.3-q33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between DGKI and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	DGKI
Name	diacylglycerol kinase, iota
Aliases	DGK-IOTA; DAG kinase iota; diglyceride kinase iota; Diacylglycerol kinase iota
Chromosomal Location	7q32.3-q33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of DGKI in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	DGKI
Name	diacylglycerol kinase, iota
Aliases	DGK-IOTA; DAG kinase iota; diglyceride kinase iota; Diacylglycerol kinase iota
Chromosomal Location	7q32.3-q33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of DGKI in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.147	0.614
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.145	0.778
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.369	0.364
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-1.22	0.014
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-1.281	0.354
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-1.15	0.454
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.102	0.844
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.263	0.749
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.076	0.926
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.75	0.246
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.384	0.643
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.075	0.626

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of DGKI in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	14.8	6.8	8	0.247
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	14.8	6.8	8	0.252
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	29.4	-24.6	0.0712
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	50	-37.5	0.245
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	18.2	-18.2	0.199
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	13.2	7.4	5.8	0.69
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	22.7	7.7	15	0.377
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	DGKI
Name	diacylglycerol kinase, iota
Aliases	DGK-IOTA; DAG kinase iota; diglyceride kinase iota; Diacylglycerol kinase iota
Chromosomal Location	7q32.3-q33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DGKI. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	DGKI
Name	diacylglycerol kinase, iota
Aliases	DGK-IOTA; DAG kinase iota; diglyceride kinase iota; Diacylglycerol kinase iota
Chromosomal Location	7q32.3-q33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DGKI. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DGKI. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	DGKI
Name	diacylglycerol kinase, iota
Aliases	DGK-IOTA; DAG kinase iota; diglyceride kinase iota; Diacylglycerol kinase iota
Chromosomal Location	7q32.3-q33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DGKI. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	DGKI
Name	diacylglycerol kinase, iota
Aliases	DGK-IOTA; DAG kinase iota; diglyceride kinase iota; Diacylglycerol kinase iota
Chromosomal Location	7q32.3-q33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of DGKI expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	DGKI
Name	diacylglycerol kinase, iota
Aliases	DGK-IOTA; DAG kinase iota; diglyceride kinase iota; Diacylglycerol kinase iota
Chromosomal Location	7q32.3-q33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between DGKI and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	DGKI
Name	diacylglycerol kinase, iota
Aliases	DGK-IOTA; DAG kinase iota; diglyceride kinase iota; Diacylglycerol kinase iota
Chromosomal Location	7q32.3-q33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting DGKI collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse DGKI